RSV F protein vaccine - Novavax

Drug Profile

RSV F protein vaccine - Novavax

Alternative Names: Respiratory syncytial virus fusion protein virus-like particle vaccine - Novavax; Respiratory syncytial virus vaccine - Novavax; ResVax; RSV F protein recombinant nanoparticle vaccine; RSV F Vaccine; RSV F-protein nanoparticle vaccine; RSV VLP vaccine candidate - Novavax/University of Massachusetts Medical School; RSV-F; RSV-F nanoparticle protein micelle vaccine; RSV-F VLP vaccine - Novavax; Soluble respiratory syncytial virus fusion protein vaccine

Latest Information Update: 14 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novavax
  • Class Protein-vaccines; Proteins; Respiratory syncytial virus vaccines; Synthetic vaccines; Viral vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Respiratory syncytial virus infections

Most Recent Events

  • 18 May 2018 Novavax completes a phase II trial in Respiratory syncytial virus infections (In the elderly, Prevention) in Australia (IM) (NCT03026348)
  • 07 May 2018 Novavax announces intention to submit BLA to the US FDA and MAA to the EMA for Respiratory syncytial virus infections by first quarter of 2020
  • 28 Dec 2017 No recent reports of development identified for phase-I development in Respiratory-syncytial-virus-infections(In children, Prevention) in Canada (IM, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top